Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1987 2
1988 5
1989 2
1990 2
1991 1
1993 1
1994 1
1995 1
1997 2
1998 3
1999 1
2002 1
2007 1
2008 1
2011 3
2012 3
2013 3
2014 2
2015 4
2016 3
2017 2
2018 1
2019 1
2020 2
2021 3
2022 3
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Paz-Ares L, et al. N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280635 Free article. Clinical Trial.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.
Besse B, Felip E, Garcia Campelo R, Cobo M, Mascaux C, Madroszyk A, Cappuzzo F, Hilgers W, Romano G, Denis F, Viteri S, Debieuvre D, Galetta D, Baldini E, Razaq M, Robinet G, Maio M, Delmonte A, Roch B, Masson P, Schuette W, Zer A, Remon J, Costantini D, Vasseur B, Dziadziuszko R, Giaccone G; ATALANTE-1 study group. Besse B, et al. Ann Oncol. 2023 Oct;34(10):920-933. doi: 10.1016/j.annonc.2023.07.006. Epub 2023 Sep 11. Ann Oncol. 2023. PMID: 37704166 Free article. Clinical Trial.
Erlotinib-induced bullous pemphigoid.
Stingeni L, Bianchi L, Minotti V, Lisi P. Stingeni L, et al. Among authors: minotti v. J Am Acad Dermatol. 2012 Nov;67(5):e199-201. doi: 10.1016/j.jaad.2012.01.034. J Am Acad Dermatol. 2012. PMID: 23062911 No abstract available.
Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).
Metro G, Bonaiti A, Birocchi I, Marasciulo F, Ubaldi M, Metelli N, Minotti V, Addeo A. Metro G, et al. Among authors: minotti v. J Thorac Dis. 2022 Apr;14(4):816-819. doi: 10.21037/jtd-22-98. J Thorac Dis. 2022. PMID: 35572898 Free PMC article. No abstract available.
Future options for ALK-positive non-small cell lung cancer.
Iacono D, Chiari R, Metro G, Bennati C, Bellezza G, Cenci M, Ricciuti B, Sidoni A, Baglivo S, Minotti V, Crinò L. Iacono D, et al. Among authors: minotti v. Lung Cancer. 2015 Mar;87(3):211-9. doi: 10.1016/j.lungcan.2014.12.017. Epub 2015 Jan 3. Lung Cancer. 2015. PMID: 25601484 Review.
The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G, Ricciuti B, Brambilla M, Baglivo S, Soli I, Minenza E, Leonardi GC, D'arpino A, Colabrese D, Tazza M, Zicari D, Minotti V, Chiari R. Metro G, et al. Among authors: minotti v. Expert Opin Drug Saf. 2017 Jan;16(1):101-109. doi: 10.1080/14740338.2017.1267725. Epub 2016 Dec 11. Expert Opin Drug Saf. 2017. PMID: 27910704 Review.
Assessment of nausea.
Del Favero A, Roila F, Basurto C, Minotti V, Ballatori E, Patoia L, Tonato M, Tognoni G. Del Favero A, et al. Among authors: minotti v. Eur J Clin Pharmacol. 1990;38(2):115-20. doi: 10.1007/BF00265968. Eur J Clin Pharmacol. 1990. PMID: 2338106 Clinical Trial.
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.
Reni M, Giommoni E, Bergamo F, Milella M, Cavanna L, Di Marco MC, Spada M, Cordio S, Aprile G, Cardellino GG, Maiello E, Bernardini I, Ghidini M, Bozzarelli S, Macchini M, Orsi G, De Simone I, Rulli E, Porcu L, Torri V, Pinto C; GARIBALDI Study Group. Reni M, et al. ESMO Open. 2023 Feb;8(1):100777. doi: 10.1016/j.esmoop.2022.100777. Epub 2023 Feb 1. ESMO Open. 2023. PMID: 36731325 Free PMC article.
55 results